Capricor Therapeutics (CAPR) Cash & Equivalents: 2011-2025
Historic Cash & Equivalents for Capricor Therapeutics (CAPR) over the last 15 years, with Sep 2025 value amounting to $19.5 million.
- Capricor Therapeutics' Cash & Equivalents fell 71.47% to $19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.5 million, marking a year-over-year decrease of 71.47%. This contributed to the annual value of $11.3 million for FY2024, which is 23.19% down from last year.
- Capricor Therapeutics' Cash & Equivalents amounted to $19.5 million in Q3 2025, which was down 16.05% from $23.2 million recorded in Q2 2025.
- In the past 5 years, Capricor Therapeutics' Cash & Equivalents ranged from a high of $68.4 million in Q3 2024 and a low of $6.2 million during Q1 2024.
- Over the past 3 years, Capricor Therapeutics' median Cash & Equivalents value was $11.3 million (recorded in 2024), while the average stood at $19.3 million.
- Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 81.82% in 2023, then soared by 661.05% in 2024.
- Quarterly analysis of 5 years shows Capricor Therapeutics' Cash & Equivalents stood at $34.9 million in 2021, then crashed by 72.47% to $9.6 million in 2022, then soared by 53.02% to $14.7 million in 2023, then declined by 23.19% to $11.3 million in 2024, then tumbled by 71.47% to $19.5 million in 2025.
- Its Cash & Equivalents was $19.5 million in Q3 2025, compared to $23.2 million in Q2 2025 and $28.8 million in Q1 2025.